MYC and lymphoma: Mice transplanted with the sgTfap4/Eμ-MYC/Cas9 HSPCs developed lymphoma at a slightly slower pace than mice that had been transplanted with sgTrp53 transduced Eμ-MYC/Cas9 HSPCs (median survival of sgTfap4-1 = 38.5 days; sgTfap4-2 = 45.5 days vs. sgTrp53 = 26 days), but significantly faster than mice transplanted with sgControl transduced Eμ-MYC/Cas9 HSPCs (112.5 days) (Fig. 1B).